Table 3. Clinical data after 24-h treatment and at 1-month follow-up.
| Levosimendan (n = 30) | Control (n = 29) | p value | |
| Clinical data after 24-h | |||
| Urine discharge (ml) | 1923 ± 285 | 1761 ± 256 | 0.026 | 
| Systolic BP (mmHg) | 111.47 ± 24.13 | 118.03 ± 13.63 | 0.205 | 
| Diastolic BP (mmHg) | 66.37 ± 14.59 | 70.83 ± 10.64 | 0.186 | 
| Heart rate (bpm) | 69.03 ± 15.82 | 73.86 ± 10.67 | 0.176 | 
| SCr (μmol/L) | 95.26 ± 26.68 | 103.56 ± 46.25 | 0.401 | 
| BNP (ng/ml) | 957.95 (727.74, 1322.84) | 1302.16 (1006.99, 1666.35) | 0.005 | 
| 1-month follow-up | |||
| Death, n (%) | 1 (3.3) | 1 (3.4) | 0.487 | 
| Hospitalization (days) | 13.60 ± 3.97 | 11.52 ± 6.02 | 0.121 | 
| Readmission, n (%) | 0 (0) | 1 (3.4) | 0.492 | 
BNP, B-type natriuretic peptides; BP, blood pressure; SCr, serum creatinine.